|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-4-5
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Vascular endothelial growth factor (VEGF) has a crucial role in angiogenesis, and is a valid target in metastatic breast cancer. Motesanib is an investigational oral inhibitor of VEGF receptors. We aimed to determine whether treatment with motesanib plus paclitaxel is better than placebo plus paclitaxel in patients with HER2-negative locally recurrent or metastatic breast cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/ERBB2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Niacinamide,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/motesanib diphosphate
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1474-5488
|
|
pubmed:author |
pubmed-author:AdewoyeHenryH,
pubmed-author:AdroverEncarnaE,
pubmed-author:AlbaEmilioE,
pubmed-author:AlmelSachinS,
pubmed-author:BañosAnaA,
pubmed-author:CabaribereDavidD,
pubmed-author:CrownJohnJ,
pubmed-author:EiermannWolfgangW,
pubmed-author:HeiYong-JiangYJ,
pubmed-author:HurvitzSaraS,
pubmed-author:Jagie??o-GruszfeldAgnieszkaA,
pubmed-author:KennedyM JohnMJ,
pubmed-author:LangIstvanI,
pubmed-author:LatreilleJeanJ,
pubmed-author:LemmerickYasminY,
pubmed-author:LindsayMary-AnnMA,
pubmed-author:MackeyJohn RJR,
pubmed-author:MartinMiguelM,
pubmed-author:MorooseRebeccaR,
pubmed-author:MunozMontserratM,
pubmed-author:PienkowskiTadeuszT,
pubmed-author:PinterTamasT,
pubmed-author:PriouFrankF,
pubmed-author:ProvencherLouiseL,
pubmed-author:RamosManuelM,
pubmed-author:RocheHenriH,
pubmed-author:RolskiJanuszJ,
pubmed-author:RupinMatthieuM,
pubmed-author:SnyderRaymondR,
pubmed-author:TRIO 010 investigators
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
369-76
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21429799-Adult,
pubmed-meshheading:21429799-Aged,
pubmed-meshheading:21429799-Antibodies, Monoclonal,
pubmed-meshheading:21429799-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21429799-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21429799-Breast Neoplasms,
pubmed-meshheading:21429799-Double-Blind Method,
pubmed-meshheading:21429799-Female,
pubmed-meshheading:21429799-Humans,
pubmed-meshheading:21429799-Indoles,
pubmed-meshheading:21429799-Middle Aged,
pubmed-meshheading:21429799-Neoplasm Metastasis,
pubmed-meshheading:21429799-Neoplasm Recurrence, Local,
pubmed-meshheading:21429799-Niacinamide,
pubmed-meshheading:21429799-Paclitaxel,
pubmed-meshheading:21429799-Receptor, erbB-2
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
|
|
pubmed:affiliation |
Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain. mmartin@geicam.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
